|
|
The government is continuing its strong commitment to building a robust biodefense industry, one with the capability and capacity to meet the nation's needs. For industry participants looking to participate in the government's biodefense efforts, the Biodefense Vaccines and Therapeutics conference is the ideal venue to get the latest and most detailed information on the various agencies' biodefense vaccines and therapeutics requirements and interact face-to-face with the government representatives tasked with building a biodefense capacity.
Past government efforts have focused on rapid development of biodefense vaccines. Recently, the government has moved away from the 'one bug - one drug' philosophy and shifted its strategies and plans towards the rapid development of a portfolio of vaccines, therapeutics and other medical countermeasures capable of combating a whole host of biodefense agents. This 'one drug - many bugs' philosophy is creating new opportunities for industry participation. For companies looking to participate in the national biodefense efforts, accessing these new opportunities require getting the up to date information on the government's latest funding programs and strategic plans.
Biodefense Vaccines and Therapeutics has established itself as the place where government and industry come together to share their strategic plans and discuss industry's participation in the government's biodefense efforts. The conference will once again provide detailed information about the role biotechnology and pharmaceutical companies, research contractors and institutes, and universities can play in addressing the nation's need for biodefense vaccines, therapeutics and other medical countermeasures. The government's senior biodefense experts will be on hand to explain biodefense funding availability, process for accessing funding, and which products at what stages of development the agencies are looking for to meet national demands, all crucial information you'll need to make informed decisions about your participation and involvement. Biodefense leaders from the biotechnology and pharmaceutical industry will provide their perspectives and feedback to the government's plans to accelerate the development of needed countermeasures, strengthen government and industry collaboration, and build a profitable and viable biodefense business sector.
|
Late Stage Biodefense Vaccines & Therapeutics Development June 4, 2007 * 8:00 a.m. to 5:00 p.m.
Chaired by:
Michael Callahan, M.D., DTM&H, Program Manager, Defense Science Office, DEFENSE ADVANCED RESEARCH PROJECTS AGENCY
Peter Hobart, Ph.D, Science Director, U.S. ARMY MEDICAL RESEARCH INSTITUTE FOR INFECTIOUS DISEASES
Michael Kurilla, M.D, Ph.D., Director, Office of BioDefense Research Affairs and Associate Director for BioDefense , NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES, NIH
This pre-conference Symposium will provide a briefing by leading biodefense researchers on late stage biodefense vaccines and therapeutics developments, including developments of antiviral therapeutics, developments in immunomodulators/immunostimulators as potential adjuvants, prophylactics and therapeutics, developments in anthrax and ricin vaccine candidates, and developments in rapid scale up and manufactures of medical countermeasures.
|
|
THE NETWORKING FAIRExplore partnership and collaboration opportunities
June 4 - 6, 2007
Once again, this year's event will feature the Networking Fair, an ideal opportunity for representatives from government, biotechnology and pharmaceutical companies, research institutions and universities to come together to explore opportunities for partnering and collaboration. Past attendees have found the Fair a great value-add to their conference experience. The Fair will feature:
- Government "help desks" where conference attendees can ask government representatives about current opportunities to collaborate with the government on the development and production of biodefense vaccines and therapeutics
- Companies and universities sharing information and showcasing their capabilities
|
Participating government agencies to date:
|
|

Department of Human and Health Services, HHS
|

National Institue of Health, NIH
|

DTRA
|

JSTO-CBD
|
Click Here to Download Brochure.
|
Rajeev Venkayya,M.D., Special Assistant to the President for Biodefense
White House Homeland Security Council
|
John Vitko, Ph.D. Head, Chem-Bio Division, Office of Health Affairs,
Department of Homeland Security
Michael Kurilla, M.D., Ph.D. Director, Office of BioDefense Research Affairs and Associate Director for BioDefense
National Institute of Allergy and Infectious Diseases, NIH
Carol Linden, Ph.D.
Acting Principal Deputy Director, Office of Public Health Emergency Medical Countermeasures (OPHEMC), Office of Public Health Emergency Preparedness (OPHEP), Department of Health and Human Services
COL Jonathan Newmark, M.D., FAAN
Deputy JPEO Medical Systems, , Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD), DOD
Brad Leissa, M.D.
Deputy Director, Office of Counter-Terrorism and Emergency Coordination, Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration
Jean Reed
Special Assistant to the Secretary of Defense for Chemical and Biological Defense and Chemical Demilitarization Programs, SA (CBD&CDP), , DOD
Barbara McQuiston
Deputy Director, Defense Sciences Office , Defense Advanced Research Projects Agency (DARPA)
Gyan Prakash, Ph.D., MBA
Director, Transformational Medical Technologies Initiative (TMTI), U.S. Department of Defense, Defense Threat Reduction Agency (DTRA), Joint Science and Technology Office for Chemical and Biological Defense, , DOD
|
|